Market reactionShares fell 10% on Nov 5.
Rocket Pharmaceuticals is a gene therapy company with KRESLADI approved for severe leukocyte adhesion deficiency-I and RP-A501 in a pivotal trial for Danon disease, a fatal inherited heart disease.
Rocket's case rests on RP-A501, a gene therapy for Danon disease, a fatal inherited heart disease with no approved treatment. In September 2026 FDA agreed the pivotal Phase 2 can continue at a recalibrated dose with 12 patients, intended to support accelerated approval. Rocket expects to finish dosing by mid-2027, and KRESLADI is approved for severe leukocyte adhesion deficiency-I. With $35 million drawn in October from a Hercules credit facility of up to $150 million, runway is expected into the third quarter of 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: RP-A501 meets the 12-month co-primary endpoints
Does RP-A501 meet both co-primary endpoints at the recalibrated dose?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
FDA agreed Rocket's path to finish the Danon pivotal trial; dosing completes by mid-2027
Gene therapy pure-play with first approval in hand, pivoting to fatal cardiac arrythmia disease — pivotal design alignment with FDA is the make-or-break gate
Danon disease pivotal readout is the make-or-break event for a newly approved gene therapy company with runway through Q2 2028
RP-A501 Phase 2 pivotal data in Danon disease will determine whether Rocket can build a second approved gene therapy franchise after KRESLADI
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neuromuscular diseases, Blood disorders, Obesity, diabetes and heart disease, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
6 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.